The IBN SINA Pharmaceutical Industry PLC (DSE: IBNSINA)
Bangladesh
· Delayed Price · Currency is BDT 346.00
+7.60 (2.25%)
At close: Sep 12, 2024
IBNSINA Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 10,866 | 9,125 | 8,480 | 7,376 | 6,192 | 5,264 | Upgrade
|
| Revenue Growth (YoY) | 24.73% | 7.61% | 14.96% | 19.13% | 17.62% | 13.02% | Upgrade
|
| Cost of Revenue | 6,415 | 5,254 | 4,914 | 4,275 | 3,595 | 3,125 | Upgrade
|
| Gross Profit | 4,451 | 3,871 | 3,566 | 3,101 | 2,597 | 2,139 | Upgrade
|
| Selling, General & Admin | 3,498 | 3,051 | 2,745 | 2,368 | 1,997 | 1,673 | Upgrade
|
| Operating Expenses | 3,498 | 3,051 | 2,745 | 2,368 | 1,997 | 1,673 | Upgrade
|
| Operating Income | 952.91 | 819.81 | 821.16 | 732.91 | 599.3 | 466.2 | Upgrade
|
| Interest Expense | -48.25 | -44.43 | -47.33 | -40 | -34.91 | -14.74 | Upgrade
|
| Interest & Investment Income | 2.37 | 2.37 | 3.33 | 2.46 | 0.92 | 2.89 | Upgrade
|
| Earnings From Equity Investments | - | - | -1.29 | -1.93 | -1.79 | -1.7 | Upgrade
|
| Currency Exchange Gain (Loss) | 11.15 | 11.15 | -2.83 | -0.2 | -1.09 | -1.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.31 | 13.59 | 17.22 | 9.99 | 1.98 | 0.68 | Upgrade
|
| EBT Excluding Unusual Items | 924.5 | 802.5 | 790.27 | 703.23 | 564.4 | 452.14 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 9.6 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.23 | 2.23 | - | 1.22 | 0.68 | - | Upgrade
|
| Pretax Income | 926.73 | 804.73 | 799.86 | 704.45 | 565.08 | 452.14 | Upgrade
|
| Income Tax Expense | 236.16 | 198.92 | 194.19 | 215.48 | 172.56 | 115.87 | Upgrade
|
| Earnings From Continuing Operations | 690.57 | 605.81 | 605.67 | 488.97 | 392.53 | 336.27 | Upgrade
|
| Minority Interest in Earnings | -0.77 | -0.39 | 0.19 | 0.15 | - | - | Upgrade
|
| Net Income | 689.8 | 605.42 | 605.87 | 489.12 | 392.53 | 336.27 | Upgrade
|
| Net Income to Common | 689.8 | 605.42 | 605.87 | 489.12 | 392.53 | 336.27 | Upgrade
|
| Net Income Growth | 12.41% | -0.07% | 23.87% | 24.61% | 16.73% | -25.65% | Upgrade
|
| Shares Outstanding (Basic) | 31 | 31 | 31 | 31 | 31 | 31 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 31 | 31 | 31 | 31 | 31 | Upgrade
|
| EPS (Basic) | 22.08 | 19.38 | 19.39 | 15.66 | 12.56 | 10.76 | Upgrade
|
| EPS (Diluted) | 22.08 | 19.38 | 19.39 | 15.66 | 12.56 | 10.76 | Upgrade
|
| EPS Growth | 12.41% | -0.07% | 23.87% | 24.61% | 16.73% | -25.65% | Upgrade
|
| Free Cash Flow | -340.79 | 191.61 | 53.4 | 309.64 | -114.94 | 43.63 | Upgrade
|
| Free Cash Flow Per Share | -10.91 | 6.13 | 1.71 | 9.91 | -3.68 | 1.40 | Upgrade
|
| Dividend Per Share | 6.000 | 6.000 | 6.000 | 4.700 | 3.850 | 3.000 | Upgrade
|
| Dividend Growth | 0% | 0% | 27.66% | 22.08% | 28.33% | 0% | Upgrade
|
| Gross Margin | 40.96% | 42.42% | 42.05% | 42.04% | 41.94% | 40.64% | Upgrade
|
| Operating Margin | 8.77% | 8.98% | 9.68% | 9.94% | 9.68% | 8.86% | Upgrade
|
| Profit Margin | 6.35% | 6.63% | 7.14% | 6.63% | 6.34% | 6.39% | Upgrade
|
| Free Cash Flow Margin | -3.14% | 2.10% | 0.63% | 4.20% | -1.86% | 0.83% | Upgrade
|
| EBITDA | 1,130 | 1,021 | 1,021 | 922.15 | 746.03 | 594.68 | Upgrade
|
| EBITDA Margin | 10.40% | 11.19% | 12.04% | 12.50% | 12.05% | 11.30% | Upgrade
|
| D&A For EBITDA | 177.45 | 200.86 | 199.57 | 189.24 | 146.73 | 128.47 | Upgrade
|
| EBIT | 952.91 | 819.81 | 821.16 | 732.91 | 599.3 | 466.2 | Upgrade
|
| EBIT Margin | 8.77% | 8.98% | 9.68% | 9.94% | 9.68% | 8.86% | Upgrade
|
| Effective Tax Rate | 25.48% | 24.72% | 24.28% | 30.59% | 30.54% | 25.63% | Upgrade
|
| Advertising Expenses | - | 45.9 | 47.72 | 42.36 | 28.28 | 29.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.